FY2025 Earnings Estimate for biote Corp. (NASDAQ:BTMD) Issued By B. Riley

biote Corp. (NASDAQ:BTMD - Free Report) - Equities researchers at B. Riley decreased their FY2025 earnings per share (EPS) estimates for shares of biote in a report released on Wednesday, August 21st. B. Riley analyst J. Van. Sinderen now anticipates that the company will post earnings per share of $0.43 for the year, down from their previous estimate of $0.52. The consensus estimate for biote's current full-year earnings is $0.56 per share. B. Riley also issued estimates for biote's FY2026 earnings at $0.67 EPS.

biote Stock Performance

Shares of NASDAQ:BTMD remained flat at $5.75 during trading on Thursday. The company's stock had a trading volume of 205,753 shares, compared to its average volume of 167,290. biote has a 12-month low of $3.65 and a 12-month high of $8.44. The firm's 50-day moving average is $7.15 and its 200 day moving average is $6.25. The firm has a market cap of $356.71 million, a P/E ratio of 52.27 and a beta of 0.98.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of biote by 1,016.6% in the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company's stock worth $4,931,000 after buying an additional 600,956 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of biote by 251.8% in the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company's stock valued at $1,442,000 after acquiring an additional 138,200 shares in the last quarter. Bandera Partners LLC raised its holdings in shares of biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company's stock valued at $9,054,000 after acquiring an additional 127,410 shares in the last quarter. Sanders Morris Harris LLC bought a new stake in shares of biote during the 2nd quarter valued at about $585,000. Finally, GDS Wealth Management purchased a new position in shares of biote during the second quarter worth about $432,000. 21.68% of the stock is owned by institutional investors.

Insider Activity at biote

In other biote news, CFO Robert Charles Peterson sold 11,376 shares of the firm's stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total value of $86,116.32. Following the completion of the transaction, the chief financial officer now owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 13.90% of the stock is currently owned by corporate insiders.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.